Hepatic Steatosis, also known as fatty liver, is a disease characterized by an excessive accumulation of lipid droplets within the liver. This can be caused by multiple factors, including excessive alcohol intake, obesity, and other diseases with abnormal fat metabolism. Hepatic Steatosis is commonly used as a marker to determine the hepatotoxicity of drug candidates. BioVision’s Hepatic Steatosis Kit provides reagents for measurement of intracellular triglyceride accumulation and staining reagents to visualize the lipid droplet formation in hepatocytes. The kit can be used to screen and evaluate steatosis risk of drug candidates and to study the mechanism of steatosis development. Chloroquine is included as a positive control for inducing steatosis in liver cells, such as HepG2. The kit provides enough reagents for 100 assays for triglyceride quantitation and staining reagents enough for two 96-well plates, two 6-well plates, or four 100 mm culture dishes.